Search PubMed⌕ Search

Biomedical subjects

M I Phillips

Publications and source records attributed to M I Phillips.

At least 73 records · Page 4Linked to original sources
PubMed1996

Inhibition of hypertension by peripheral administration of antisense oligodeoxynucleotides.

We administered liposome-encapsulated antisense oligodeoxynucleotide targeted to angiotensinogen mRNA peripherally to spontaneously hypertensive rats to test whether peripheral angiotensinogen reduction would lower their hypertensive blood pressures and to determine the role of peripheral angiotensinogen in the modulation of hypertension. Using in vitro translation techniques, we tested the sequence specificity of the antisense sequence. The selected antisense sequence decreased angiotensinogen production in vitro, enabling us to distinguish between specific and nonspecific effects. To increase the efficiency of peripheral and hepatic antisense delivery, oligonucleotides were liposome encapsulated and intra-arterial administration. Confocal microscopy was used for determination of the hepatic distribution of fluorescently labeled antisense. Encapsulated antisense molecules were seen to be distributed within liver tissue 1 hour after injection; however, little or no uptake was observed with the unencapsulated oligonucleotides. We also determined the physiological effects of antisense oligodeoxynucleotide targeted to liver angiotensinogen mRNA. Administration of liposome-encapsulated antisense significantly decreased hypertensive blood pressures to normotensive levels compared with scrambled control oligonucleotides, unencapsulated antisense, and empty liposomes (P = .013). These data were supported by biochemical changes elicited by the antisense treatment. Rats receiving liposome-encapsulated antisense had significantly lowered peripheral angiotensinogen and angiotensin II levels compared with control groups (P < .05). No significant heart rate changes were observed in the antisense or control groups. These results suggest that peripheral angiotensinogen plays a role in the maintenance of hypertensive blood pressure in this model of hypertension and that peripheral administration of antisense molecules is possible with organ-targeted delivery mechanisms.

Angiotensin II↗
PubMed1996

Interactions of angiotensin II and atrial natriuretic peptide in the brain: fish to rodent.

The brain peptides atrial natriuretic peptide (ANP) and angiotensin II (AngII) have antagonistic actions centrally that have evolved to play an important role in maintaining the homeostasis of fluid volume and electrolytes. This paper discusses the possible evolution of these functions as viewed through studies on fish and rats. In the euryhaline teleost fish, the major form of ANP is CNP. CNP is important for the adaptation of fish in sea water to water with lower salinity (50% SW). The concentration of CNP in the hypothalamus (HTS-CNP) of toadfish is significantly increased when the fish moves from SW to 50% SW. Interestingly, the plasma CNP concentrations of these fish go in the opposite direction to the brain CNP. Plasma CNP is reduced 24 hrs and 10 days after the fish has been in 50% SW. We postulate that the increased hypothalamic CNP is correlated with an increase in hypothalamic dopamine turnover. Dopamine is the main inhibitory factor for the release of prolactin. In sea-water-adapted fish, prolactin plasma levels are low. In 50% SW, the levels are increased. Extracts of fish-brain CNP caused an increase in urinary sodium and volume, indicating the natriuretic action of CNP. In contrast to CNP, hypothalamic AngII was decreased during adaptation to 50% SW. Thus, CNP and AngII in the brain have opposite actions in fish which aid in their survival in adapting to different salinities. This implies that the hormones evolved as sodium/osmoregulatory peptides, not volume-regulatory peptides. In moving from an aquatic to a terrestrial environment, ANP further evolved in mammals as a volume-regulating hormone while retaining its sodium-regulating properties. In the brain the antagonism between the peptides is apparent in many actions, but when volume is changed both peptides are increased. This is in contrast to plasma ANP and plasma AngII, which have opposite actions during hemorrhage. Plasma AngII is increased and plasma AnP is decreased after blood volume loss. Brain ANP counteracts the thirst-inducing and volume-restoring roles of brain AngII in mammals. By these actions, the brain peptides play significant roles in maintaining volume and electrolyte homeostasis.

Amino Acid Sequence↗
PubMed1995

A decrease in angiotensin receptor binding in rat brain nuclei by antisense oligonucleotides to the angiotensin AT1 receptor.

Intracerebroventricular (i.c.v.) injections of antisense oligonucleotides against mRNA of the angiotensin type 1 (AT1) receptor have been shown to reduce blood pressure in spontaneously hypertensive (SHR) rats and angiotensin II-induced drinking in both SHR and Sprague-Dawley (SD) rats. The present investigation was designed to quantify the effect of i.c.v. injections of antisense oligonucleotides to the AT1 receptor mRNA on brain angiotensin receptors using membrane binding and autoradiographic analysis. Control injections contained sense or scrambled oligonucleotides or saline. Three daily injections of antisense oligonucleotides into the third ventricle of SD rats decreased the AT1 receptor number significantly by 25% in a hypothalamic tissue block. AT2 receptors were not altered. Autoradiography showed a decrease in angiotensin receptor number in hypothalamic nuclei and in the anteroventral region of the third ventricle (AV3V) after antisense treatment. AT2 receptors were not reduced indicating the AT1 antisense oligonucleotides were specific. In a second series of experiments, single injections of antisense oligonucleotides into the lateral ventricle of SHR rats were tested. Antisense oligonucleotides produced a significant decrease in receptor number in the same hypothalamic area. Sense and scrambled oligonucleotides did not decrease the receptor numbers significantly. The decreases observed after injection of antisense oligonucleotides were between 15 and 30%. These changes may be sufficient to account for the physiological effects of i.c.v. injections of antisense oligonucleotides to AT1 receptor mRNA.

Analysis of Variance↗
PubMed1995

Brain angiotensin and the female reproductive cycle.

The results consistently show from experiment to experiment that there is a surge of brain Ang II prior to the well known preovulatory LH surge. It should be pointed out that these experiments have been carried out by two different laboratories and with the help of different experimenters and some of the experiments have been repeated. Therefore, the consistency of the results is reassuring. It does appear that Ang II increases in the brain, specifically in the hypothalamus, probably in cells of the paraventricular nucleus about 1 hour before the LH levels in plasma rise to a peak. Since LH release from the anterior pituitary gland is stimulated by the release of LHRH from the arcuate nucleus into the median eminence, the results would suggest that Ang II stimulates the release of LHRH. The peak in the OVX of Ang II treated rats is sharp and short-lasting with a second, later peak. The LH surge follows the first peak and a second rise in LH follows the second Ang II peak. These data suggest that brain Ang II synthesized and stored in the brain plays a critical role in the female reproductive cycle by initiating the LH surge. The regulation of Ang II may be by estrogen and progesterone, but as the increase in angiotensinogen mRNA was not marked, the surge of Ang II appears to result more from the sudden release of stored Ang II than its synthesis. Thus, the question is what releases Ang II. Earlier studies showed that catecholamines release Ang II from neurons and not from glia involving alpha 2 receptor blockade to increase norepinephrine by inhibiting reuptake (7). An interaction between catecholamines, Ang II and LH had also been suggested earlier (18, 19). Therefore, a series of events triggered by steroids in proestrus may begin with increases in norepinephrine activating neuronal alpha 2 receptors and precipitating release of brain Ang II. This is represented diagrammatically in Figure 15. The Ang II surge stimulates the cells containing GnRH (gonadotropin releasing hormone) in the arcuate nucleus. The effect of Ang II on multiple GnRH cells amplifies the effect and GnRH is released into the portal vessels of the pituitary to stimulate the large LH release, from gonadotrope cells in the anterior pituitary, into the plasma that produces the LH surge. The effect of the LH surge is ovulation which ends the estrogen build up.(ABSTRACT TRUNCATED AT 400 WORDS)

Angiotensin II↗
PubMed1995

Antisense inhibition of hypertension in the spontaneously hypertensive rat.

Phosphorothioated antisense oligodeoxynucleotide (ASODN) targeted to angiotensinogen mRNA was administered intracerebroventricularly in spontaneously hypertensive rats to test whether angiotensinogen reduction would lower their hypertensive blood pressures. The ASODN lowers hypertensive blood pressures to normotensive levels in spontaneously hypertensive rats; sense oligodeoxynucleotide had no effect. Administration of phosphorothioated ASODN produced a prolonged duration of lowered blood pressure. Injections of ASODN at the same dose that decreased hypertension when administered centrally did not result in blood pressure decreases when administered intra-arterially. Furthermore, angiotensinogen production was decreased in the brain stem and significantly decreased in the hypothalamus of the ASODN-treated rats (P < .05), supporting the concept of centrally mediated regulation of hypertension by an overactive brain angiotensin system. To determine the distribution of centrally administered oligodeoxynucleotides, fluorescein isothiocyanate-conjugated oligodeoxynucleotides were injected directly into the lateral ventricles. One hour later, oligodeoxynucleotides were distributed throughout the lateral and third ventricles, with tissue and cellular uptake observed in discrete cells at the injection site. This indicates that the oligodeoxynucleotides are taken up rapidly by brain cells and that they permeate the areas surrounding brain nuclei involved in central blood pressure regulation and volume homeostasis. The results confirm and extend our previous study with phosphodiester ASODN and show that phosphorothioation modification increases the duration of the response and is taken up in vivo. We conclude that with modification, ASODN inhibition of angiotensinogen mRNA translation can be used for a prolonged, profound decrease in mean arterial pressure in the spontaneously hypertensive rat through a central mechanism.

Angiotensinogen↗
PubMed1994

Antisense oligonucleotide to AT1 receptor mRNA inhibits central angiotensin induced thirst and vasopressin.

Antisense oligodeoxynucleotides (AS-ODN) to AT1 receptor mRNA inhibit high blood pressure in Spontaneously Hypertensive Rats (SHR) when injected into the brain. The effect is presumably through inhibition of the actions of brain angiotensin II (Ang II). Central injection of Ang II elicits several physiological responses including release of vasopressin and motivation to drink. The angiotensin II type-I (AT1) receptor is located in brain regions which have been implicated in mediating these effects. Therefore we hypothesized that AS-ODN to AT1 mRNA would inhibit the drinking and AVP response to central administration of Ang II in adult male SHR. AS-ODN were constructed to bases +63 to +77 (15-mer) of the AT1 receptor RNA. 24 h after AS-ODN treatment (50 micrograms/4 microliters) (intracerebroventricularly, i.c.v.), the drinking response to Ang II (50 ng, i.c.v.) was significantly reduced in the SHR (P < 0.05). The drinking response to Ang II (i.c.v.) was also reduced in the Sprague-Dawley rats (P < 0.05). There was no reduction of water intake in the control animals treated with scrambled ODN (SC-ODN). Repeated injection of AS-ODN did not produce a greater reduction in drinking response. Arginine vasopressin (AVP) release to central Ang II was significantly decreased after AS-ODN treatment when compared to vehicle (P < 0.05) and to SC-ODN injections (P < 0.05). Radioligand binding assays of the hypothalamic block after AS-ODN treatment showed a significant decrease of AT1 receptor binding (P < 0.05). The results show that the antisense inhibition of brain AT1 receptor gene expression decreases the Ang II induced drinking and AVP release responses.

Animals↗
PubMed1994

Involvement of angiotensin receptor subtypes in osmotically induced release of vasopressin.

We have previously shown that AT1 and AT2 angiotensin II (Ang II) receptors mediate the release of arginine vasopressin (AVP) to central injections of Ang II. In this study we have tested the hypothesis that Ang II, acting at AT1 and AT2 receptors in the brain, is involved in mediating osmotically stimulated AVP release. Adult Sprague-Dawley rats were fitted with intraventricular (i.v.t.) cannulas and catheters in the carotid artery and the femoral vein. Intraventricular injections of Ang II receptor antagonists specific to different subtypes of the receptor (AT1 and AT2) were given before a 30 min infusion of hypertonic (2.5 M) saline. Arterial blood samples were collected 5 min before and at two time points after (+15 min and +30 min) beginning the saline infusion. We found that both losartan (AT1 specific) and CGP42112A (AT2 specific) significantly reduced osmotically induced release of AVP. PD123319 (AT2 specific) had no effect of osmotically stimulated AVP release. A combined treatment of losartan + PD123319 was no more effective than losartan in blocking the AVP response. Since losartan was the most rapid and effective antagonist of osmotically stimulated AVP release, we conclude that AT1 receptors are directly involved in the response. However, but since CGP42112A was also an effective antagonist and since, AT2 receptors are located at sites distant from the hypothalamus, such as the locus ceruleus, they may also contribute to this response. We conclude that brain Ang II receptors are involved in osmotically stimulated AVP release.

Angiotensin II↗
PubMed1994

Optimization for the detection of hepatitis C virus antigens in the liver.

To optimize the detection of hepatitis C viral antigens in liver tissue, cryostat and formalin-fixed, paraffin-embedded liver sections from 21 patients with chronic hepatic C viral infection were studied. For cryostat sections, six different fixatives were compared. Sixteen primary antibodies were tested: nine different mouse monoclonal anti-hepatitis C virus-core antibodies, a human monoclonal anti-hepatitis C virus-non-structural 4, and six rabbit polyclonals directed against synthetic peptides of the hepatitis C virus core, envelope, and non-structural 3, non-structural 4, non-structural 5. Three detection systems, 3- and 5-step peroxidase-antiperoxidase and avidin-biotin complex, were examined. In cryostat sections, acetone/chloroform formation consistently produced the best signal-to-background ratio. Five anti-hepatitis C virus-core monoclonals which recognize amino acid sequence 26-45 of the hepatitis C virus-core region consistently detected the viral antigen, but not the monoclonals directed against 39-74 of the hepatitis C virus-core region. The human anti-hepatitis C virus-non-structural 4, which reacts to amino acid sequence 1700-1705, also regularly detected viral antigen. The rabbit polyclonals produced either negative or nonspecific staining. The 5-step peroxidase-antiperoxidase provided the strongest signal and the avidin-biotin system produced high background consistently. Overall, hepatitis C virus core and non-structural 4 antigens were detected in 71% and 57% of the patients studied. Of the 16 patients seropositive for hepatitis C virus RNA, 75% and 69% had detectable hepatitis C virus core and non-structural 4, in contrast to 60% and 20% of the five hepatitis C virus RNA seronegative patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Antigens, Viral↗
PubMed1994

Antisense inhibition of hypertension: a new strategy for renin-angiotensin candidate genes.

There are several ways of experimentally studying the influence of candidate genes on hypertension. The approach proposed here is antisense inhibition with antisense oligodeoxynucleotides (AS-ODNs) constructed to the 5' region of known sequences of angiotensinogen mRNA and angiotensin II type-1 receptor mRNA. The AS-ODNs were applied in vivo and in vitro. In vivo, direct injection of 50 micrograms of AS-ODN into the lateral ventricles of SHR reduced hypertension significantly (P < 0.01). There was no effect of AS-ODN i.c.v. in normotensive WKY rats. The phosphorothiated AS-ODN to the AT1 receptor mRNA also produced a long-lasting decrease in blood pressure in SHR (7 days). After AS-ODN treatment AT1 receptors were reduced in the PVN and anterior third ventricle area and Ang II levels were reduced in the brainstem. The results show the in vivo feasibility of using antisense inhibition of renin-angiotensin mRNA to reduce hypertension.

Angiotensinogen↗
PubMed1994

Variations in angiotensin-II release from the rat brain during the estrous cycle.

To investigate the hypothesis that the release of angiotensin-II (AII) in the rat brain increases on the day of proestrus, samples of cerebrospinal fluid (CSF) and interstitial fluid from the general region of the bed nucleus of the stria terminalis pars ventralis in the preoptic-anterior hypothalamic area were monitored for AII-immunoreactive material (AII-ir) using push-pull cannulas. Samples of CSF were obtained on the day of proestrus and diestrus day 1 at 30-min intervals from 1200-1600 h. Samples of interstitial fluid were obtained at 25-min intervals from 0930-1600 h. The rate of release of AII-ir into CSF was significantly greater on proestrus compared to diestrus day 1, and in the early afternoon of proestrus compared to the late afternoon. In five of seven rats and in the overall comparison of AII-ir release from the preoptic-anterior hypothalamic area, significantly more AII-ir was released on the day of proestrus vs. diestrus day 1. These observations are consistent with previous studies suggesting that brain AII may play a role in the regulation of LH release on the day of proestrus.

Angiotensin II↗
PubMed1993

Antisense inhibition of AT1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin.

To determine the role of angiotensinogen and angiotensin II type-1 (AT1) receptor genes in hypertension, spontaneously hypertensive rats (SHR) were injected with synthetic antisense oligodeoxynucleotides (ODNs), intracerebroventricularly (i.c.v). Antisense ODNs were constructed to bases -5 to +13 of angiotensinogen mRNA (18-mer) and to bases +63 to +77 (15-mer) of angiotensin II type-1 receptor mRNA. Hypertension was significantly reduced by the application of 50 micrograms of both antisense ODNs to normotensive levels. The phosphorothioated antisense ODN to the AT1 receptor produced long-lasting (7 days) decreases in blood pressure. After AT1 antisense treatment, AT1 receptors were reduced in the paraventricular nucleus (PVN) and in the anterior third ventricle area (AV3V). Following angiotensinogen antisense treatment, angiotensin II levels were significantly reduced in the brainstem (P < 0.05), indicating arrest of angiotensin II synthesis. The results demonstrate that inhibiting the brain renin-angiotensin system by antisense inhibition of the angiotensinogen and the AT1 receptor genes, lowers high blood pressure in the SHR. The antisense administration to specific genes of the tissue renin-angiotensin system offers the possibility of a new approach to developing antihypertension treatments.

Angiotensinogen↗
PubMed1993

Dopamine receptor agonists and antagonists both inhibit dopamine secretion in LLC-PK1 cells.

A series of dopamine receptor agonists and antagonists were tested in a renal epithelial cell line (LLC-PK1) for their ability to alter renal dopamine synthesis and secretion. LLC-PK1 cells were incubated with L-3,4-dihydroxyphenylalanine (L-dopa) (250 microM) in the presence and absence of dopaminergic drugs known to be selective for dopamine receptor subtypes and total dopamine synthesis and dopamine secretion into the media were measured directly by high performance liquid chromatography (HPLC). Both dopamine receptor agonists and antagonist significantly inhibited dopamine secretion from LLC-PK1 cells at concentrations between 10-100 microM. The phenothiazines, chlorpromazine and trifluoperazine, also significantly inhibited aromatic amino acid decarboxylase activity at 100 microM. The mechanism of action for these dopaminergic drugs appeared to involve the inhibition of dopamine secretion from LLC-PK1 cells by direct competition for outward transport by an organic cation transporter. Inhibition of dopamine secretion by these drugs was usually accompanied by significant elevations of the intracellular stores of dopamine. The results of this study suggest that caution should be exhibited in the interpretation of experiments that employ high concentrations of dopamine drugs, in order to account for the potential interaction of these agents with the renal cation transport system.

2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-ben↗
PubMed1993

Immunohistochemical mapping of angiotensin AT1 receptors in the brain.

A new approach to study angiotensin receptor distribution in the brain has been taken by developing antibodies to partial sequence of the angiotensin II (AII) type-1 receptor subtype (AT1) and demonstrating the presence of receptors with immunohistochemical staining. The antibody to a portion of the 3rd cytoplasmic loop of the AT1 receptor revealed distinctive punctate immunoreactive staining on cell bodies. The cell bodies were distributed in the forebrain in paraventricular and supraoptic nuclei, the organum vasculosum lamina terminalis, median preoptic area and subfornical organ. In the brainstem, the entire locus coeruleus was stained, together with the adjacent mesencephalic and motor nuclei of the trigeminal nerve. The auditory system including the cochlear nucleus and superior olivary nuclei were stained. In the medulla, all the structures involved in blood pressure control were stained including the nucleus of the solitary tract, the 12th nerve nuclei, the rostroventral lateral area and the nucleus ambiguous. Sites where AT2 receptors are located were not stained or staining was limited to specific area such as the medial accessory nucleus of the inferior olive. Immunocytochemical staining of AT1 receptors provides a new and more precise approach to the cellular localization of AII receptors.

Amino Acid Sequence↗
PubMed1993

Levels of angiotensin and molecular biology of the tissue renin angiotensin systems.

The cloning of renin, angiotensinogen and angiotensin converting enzyme genes have established a widespread presence of these components of the renin-angiotensin system in multiple tissues. New sites of gene expression and peptide products in different tissues has provided strong evidence for the production of angiotensin independently of the endocrine blood borne system. In addition, the cloning of the angiotensin receptor (AT1) gene has confirmed the widespread distribution of angiotensin and suggested new functions for the peptide. This review of various tissues shows the variation in gene expression between tissues and angiotensin levels, and the fragmentary state of our knowledge in this area. As yet we cannot state that the gene expression of the substrates, enzymes and peptide products are involved in a single cell synthesis. This is not so much evidence against a paracrine function for tissue angiotensin, as lack of detailed, accurate intracellular information. The low abundance of renin in brain, spleen, lung and thymus compared to kidney, adrenal, heart, testes, and submandibular gland may suggest that there are both tissue renin-angiotensin systems (RAS) and nonrenin-angiotensin systems (NRAS). The NRAS could function through cleavage of angiotensinogen by serine proteinases such as tonin and cathepsin G to form Ang II directly. Although much angiotensinogen is extracellular and could therefore be a site of synthesis outside of the cell, intracellular angiotensinogen in a NRAS process could produce Ang II intracellularly without requiring extracellular conversion of Ang I to Ang II by ACE. In summary, renin mRNA is found in high concentrations in kidney, adrenal and testes and decreasing lower concentrations in ovary, liver, brain, spleen, lung and thymus. Angiotensinogen mRNA is found in the following tissues in descending order of abundance: liver, fat cells, brain (glial cells), kidney, ovary, adrenal gland, heart, lung, large intestine and stomach. It is debatable whether angiotensinogen and renin mRNA are expressed in blood vessels. The evidence that is lacking for a paracrine function of angiotensin is a complete description of the intracellular molecular synthesis and release of Ang II from single cells of promising tissues. Such tissues, SMG, ovary, testes, adrenal, pituitary and brain (neurons and glia) are potent sources of RAS components for future studies. Although the evidence for a paracrine function of angiotensin II is incomplete, it is an important concept for progressing toward the understanding of tissue peptide physiology and the significance of their gene regulation.

Angiotensin II↗
PubMed1993

Inhibition of central angiotensin responses by angiotensin type-1 receptor antibody.

Angiotensin type-1 receptor subtypes (AT1) are implicated in the physiological actions of angiotensin II in the brain. In the present study we used an AT1 receptor antibody and a polymerase chain reaction--synthesized AT1 receptor complementary DNA to show that the hypothalamus expresses significantly higher levels of AT1 receptor messenger RNA and protein compared with the brain stem. Intracerebroventricular injections of AT1-specific antibody blocks the dipsogenic and blood pressure responses induced by centrally injected angiotensin II. These results demonstrate the expression of AT1 receptor gene in the brain and that the AT1 receptor antibody is able to inhibit the physiological responses of angiotensin II mediated by the brain.

Angiotensin II↗
PubMed1993

Dynamic changes in hypothalamic angiotensin II levels and release in association with progesterone-induced luteinizing hormone surge.

To test the hypothesis that brain angiotensin II (Ang II) may be involved in the preovulatory release of LH on proestrus, we evaluated the pattern of changes in hypothalamic Ang II levels and release in ovariectomized (ovx) rats treated sequentially with estrogen and progesterone. This is an experimental paradigm that reliably evokes dynamic changes in hypothalamic LHRH levels in association with LH hypersecretion, simulating the LH surge on proestrus. Rats were ovx and after 4 weeks received estradiol benzoate followed by progesterone 2 days later at 1000 h. We observed that in these progesterone-treated rats, serum LH levels were low until 1400 h, but thereafter, the rate of LH secretion increased and remained elevated at 1600 h when the experiment was terminated. In these rats, hypothalamic Ang II levels increased abruptly at 1330 h and returned rapidly to baseline levels before the onset of LH surge. Also, a similar pattern in hypothalamic Ang II levels occurred at 1500 h with the rise and peak serum LH levels in the late afternoon. In the second experiment, Ang II levels in the cerebrospinal fluid (CSF) of rats similarly pretreated with ovarian steroids were evaluated. Again, CSF Ang II levels rose abruptly to a peak at 1330 h and returned to baseline range preceding the expected rise in serum LH. Thereafter, no further change in CSF Ang II levels was detected during the period of LH hypersecretion. In the third experiment, perfusates were collected from a push-pull cannula aimed at the paraventricular nucleus in ovx rats similarly treated with ovarian steroids. A peak of Ang II was observed at 1330 h and a later peak at 1430 h. A comparison with LH profiles indicated that these peaks in Ang II levels were evident before and during the LH surge. Thus, in three separate experiments, the results showed that rapid dynamic changes in hypothalamic Ang II levels and release occur in association with the progesterone-induced LH surge in estrogen-primed ovx rats. These findings support the previous observations that Ang II can stimulate LHRH and LH release. Since similar, temporally correlated changes occur in hypothalamic neuropeptide Y and LHRH, the peptides involved in the induction of LH surge, these results are in agreement with the hypothesis that Ang II-expressing neurons may play an important role in the hypothalamic circuitry responsible for stimulation of LH surge in ovarian steroid-treated ovx rats.

Angiotensin II↗